On October 6, 2021, XOMA (US) LLC ("XOMA"), a wholly-owned subsidiary of XOMA Corporation (the "Company"), reported that entered into a commercial payment purchase agreement (the "Agreement") with Affitech Research AS, a Norwegian biotech company ("Affitech") (Filing, 8-K, Xoma, OCT 6, 2021, View Source [SID1234591012]). Pursuant to the Agreement, XOMA has purchased a future stream of commercial payment rights to Roche’s faricimab from Affitech for $6 million. XOMA is eligible to receive an economic interest of 0.50% of net sales of faricimab for a ten-year period following first commercial sales in each applicable jurisdiction. XOMA may pay up to an additional $20 million to Affitech based upon the achievement of certain regulatory and sales milestones.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Agreement contains certain covenants, representations and warranties regarding Affitech’s rights and obligations with respect to the existing licenses and customary covenants and representations for a transaction of this nature.

On October 6, 2021 LianBio, a Princeton, NJ-Shanghai biopharma, reported that it has filed for a $100 million IPO on the NASDAQ exchange (Press release, LianBio, OCT 6, 2021, View Source [SID1234591005]). LianBio currently has a pipeline of nine in-licensed candidates in five therapeutic areas including oncology. The company was formed by US-based Perceptive Investors to bring promising products from its large portfolio of life science companies to China’s market, while LianBio also in-licenses candidates from other companies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 6, 2021 Race Oncology ("Race") reported that it has been issued a new patent (US 11,135,201) from the United States Patent and Trademarks Office (USPTO) for its cancer drug, Zantrene (bisantrene dihydrochloride) (Press release, Race Oncology, OCT 6, 2021, View Source [SID1234591004]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This is Race’s fifth patent granted for Zantrene in the United States. "This latest US patent provides Race with additional protection around the use, formulation and compositions of Zantrene (and related chemical structures) that improve the therapeutic benefit of Zantrene", said Race’s CEO & Managing Director, Phillip Lynch.

The new patent builds on Race’s existing Zantrene patents granted in the USA in 2018 (US 9,993,460 and US 9,974,774), 2019 (US 10,500,192) and in 2020 (US 10,548,876), further strengthening Race’s IP position for Zantrene.

The patent further expands Race’s IP portfolio in the therapeutic utility of Zantrene (and related chemical structures), in particular – for methods, formulations and compositions that improve the therapeutic efficacy of Zantrene and reduce side effects.

On October 6, 2021 Biogen Inc. (Nasdaq:BIIB) reported it will report third quarter 2021 financial results Wednesday, October 20, 2021, before the financial markets open.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET. To access the live webcast, please go to the investors section of Biogen’s website at investors.biogen.com. Following the live webcast, an archived version of the call will be available on the website.

On October 6, 2021 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported that members of the management team will be presenting virtually at the following H.C. Wainwright Investor Conferences (Press release, Altimmune, OCT 6, 2021, View Source [SID1234590969]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 5th Annual NASH Investor Conference
Tuesday, October 12, 2021
3:30 pm Eastern Time
H.C. Wainwright Hepatitis B Virus (HBV) Virtual Conference
Wednesday, October 13, 2021
4:30 pm Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.